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Shape‑sensing robotic‑assisted
bronchoscopy for pulmonary nodules: initial
multicenter experience using the Ion™
Endoluminal System
Michael J. Simoff1*, Michael A. Pritchett2,3, Janani S. Reisenauer4, David E. Ost5, Adnan Majid6, Colleen Keyes7,
Roberto F. Casal5, Mihir S. Parikh6, Javier Diaz‑Mendoza1, Sebastian Fernandez‑Bussy8 and Erik E. Folch7

Abstract
Background: Traditional bronchoscopy provides limited approach to peripheral nodules. Shape-sensing roboticassisted bronchoscopy (SSRAB, Ion™ Endoluminal System) is a new tool for minimally invasive peripheral nodule
biopsy. We sought to answer the research question: Does SSRAB facilitate sampling of pulmonary nodules during
bronchoscopists’ initial experience?
Methods: The lead-in stage of a multicenter, single-arm, prospective evaluation of the Ion Endoluminal System (PRE‑
CIsE) is described. Enrolled subjects ≥ 18 years old had recent computed tomography evidence of one or more solid
or semi-solid pulmonary nodules ≥ 1.0 to ≤ 3.5 cm in greatest dimension and in any part of the lung. Subjects were
followed at 10- and 30-days post-procedure. This stage provided investigators and staff their first human experience
with the SSRAB system; safety and procedure outcomes were analyzed descriptively. Neither diagnostic yield nor sen‑
sitivity for malignancy were assessed in this stage. Categorical variables are summarized by percentage; continuous
variables are summarized by median/interquartile range (IQR).
Results: Sixty subjects were enrolled across 6 hospitals; 67 nodules were targeted for biopsy. Median axial, coronal
and sagittal diameters were < 18 mm with a largest cardinal diameter of 20.0 mm. Most nodules were extraluminal
and distance from the outer edge of the nodule to the pleura or nearest fissure was 4.0 mm (IQR: 0.0, 15.0). Median
bronchial generation count to the target location was 7.0 (IQR: 6.0, 8.0). Procedure duration (catheter-in to catheterout) was 66.5 min (IQR: 50.0, 85.5). Distance from the catheter tip to the closest edge of the virtual nodule was 7.0 mm
(IQR: 2.0, 12.0). Biopsy completion was 97.0%. No pneumothorax or airway bleeding of any grade was reported.
Conclusions: Bronchoscopists leveraged the Ion SSRAB’s functionality to drive the catheter safely in close proximity
of the virtual target and to obtain biopsies. This initial, multicenter experience is encouraging, suggesting that SSRAB
may play a role in the management of pulmonary nodules.
Clinical Trial Registration identifier and date NCT03893539; 28/03/2019.
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Background
Chest imaging has seen significant growth in the United
States and worldwide due to its non-invasive ability to
detect pulmonary conditions. In the United States more
than an estimated 1.6 million nodules are detected each
year as incidental findings on chest radiographs and
computed tomography (CT) scans [1]. Also seen is
increased identification of nodules due to the growth in
lung cancer screening programs based on low-dose CT
scans to assess patients who are high risk for lung cancer. Such screening has resulted in an 8–51% incidence
of solitary pulmonary nodules within selected populations [2]. While most nodules may require surveillance,
a significant number require tissue biopsy.
Because of their larger diameters, standard bronchoscopes cannot progress beyond the subsegmental bronchi and consequently provide a limited approach to
peripheral nodules [3]. The overall sensitivity for malignancy of flexible bronchoscopy is 34% for lesions < 2 cm
and 63% for > 2 cm [4]. The development of virtual
bronchoscopy, fluoroscopic guidance, radial endobronchial ultrasound (rEBUS), ultrathin bronchoscopes,
and electromagnetic navigation bronchoscopy (ENB)
for the diagnosis of peripheral nodules has improved
our ability to sample smaller and more peripheral
lesions. Yet, a meta-analysis resulted in a pooled diagnostic yield (based on these techniques prior to 2010)
evidenced 60.9% for lesions ≤ 2 cm—demonstrating
the continued challenge to approaching small peripheral nodules [5, 6]. Two recent studies—a real-world
single-arm cohort and a meta-analysis, respectively—
described a 73% yield from ENB for nodules with a
median size of 2 cm and a pooled sensitivity for malignancy of 77% with a good safety profile with an average lesion size of 23.2 mm [7, 8]. Such reports highlight
the need for improved procedural outcomes for small
peripheral nodules by developing new bronchoscopy
tools and approaches, while maintaining a low complication rate.
A shape-sensing robotic-assisted bronchoscope
(SSRAB) is a new tool for minimally invasive peripheral
nodule biopsy. The Ion™ Endoluminal System (Intuitive
Surgical, Inc., Sunnyvale, CA) received its 510 K from
the FDA in 2019. In the first human use study of a precommercial iteration of the Ion Endoluminal System,
targets with a mean size of approximately 14 mm were
reached in 96.6% of cases; the overall diagnostic yield
was 79.3% with no reported incidence of pneumothorax or bleeding [9].

Does SSRAB facilitate sampling of pulmonary nodules
in human subjects during bronchoscopists’ early experience? The authors hypothesize that SSRAB does facilitate biopsy of pulmonary nodules, including small and
peripherally based nodules, in these subjects. This manuscript is a report of the initial multicenter experience in
human subjects, including procedural characteristics and
descriptive outcomes. [ClinicalTrials.gov identifier and
date: NCT03893539; 28/03/2019].

Methods
The current study describes the initial or lead-in stage
(Stage 0) of the larger PRECIsE study—a multistage,
single-arm, prospective evaluation of the SSRAB System
to bronchoscopically approach and facilitate sampling
of pulmonary nodules. The purpose of this lead-in stage
was to provide participating investigators and support
staff their first human experience with the SSRAB system and its associated workflow. The study period (date
of first enrollment to last follow up) was from 29 March,
2019 to 10 January, 2020. For the lead-in cases, subjects
were followed to and not beyond 30 days post procedure. The focus was collection of early complications
and safety data. The performance metrics of yield and
sensitivity will be addressed and analyzed in subsequent
publications.
Pre-specified enrollment in this initial stage was limited to 10 subjects per each of the six participating centers, with at least 5 subjects per bronchoscopist. Enrolled
subjects were ≥ 18 years old, were suitable candidates
for elective bronchoscopy, had recent evidence on CT
of one or more solid or semi-solid pulmonary nodules ≥ 1.0 to ≤ 3.5 cm in greatest dimension and in any
part of the lung. Subjects considered for enrollment in
this study had a moderate-to-high risk of malignancy;
high-risk subjects were enrolled if they wanted diagnostic confirmation prior to treatment. Subjects with a
suspicion of metastatic disease were also considered; all
considered subjects included those for whom investigators would consider further interventions if indicated
to confirm diagnosis. Each center obtained institutional
review board (IRB) approval (study sites, IRB committee names, and approval numbers follow. Mayo Clinic:
Mayo Clinic IRB 18-011348; First Health Moore Regional
Hospital: Western IRB 20183121; Massachusetts General Hospital: Dana Farber Cancer Institute IRB 19-209;
Beth Israel Deaconess Medical Center: Dana Farber Cancer Institute IRB 19-209; Henry Ford Hospital: Henry
Ford Health System IRB 12822; University of Texas MD
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Anderson Cancer Center: MD Anderson Cancer Center
IRB IRB00006023). Enrolled study participants provided
written informed consent, and study subject confidentiality was maintained according to the Health Insurance
Portability and Accountability Act requirements.
Briefly described, the SSRAB system is comprised of
a robotic system cart, controller and fully articulating
catheter instrument with embedded shape-sensing capabilities (Fig. 1). The robotic system cart facilitates the
movement of the catheter instrument via the instrument
arm by translating input from the standalone controller
and leverages a pull-wire system to drive the catheter
into the airways under direct visualization provided by a
vision probe. The cart houses two system monitors that
provide visual information including: virtual and live airway views, the airway tree with catheter position overlaid, target information, and third-party video sources
such as radial endobronchial ultrasound (rEBUS)and
fluoroscopy (Figs. 2 and 3). The fully articulating catheter
is 3.5 mm in outer diameter with a 2-mm working channel and a steerable distal tip, which can be articulated up
to 180 degrees in any direction (Fig. 4). A thin flexible
fiber, which provides the basis for the shape-sensing technology, is embedded along the catheter’s entire length

Fig. 1 Ion Endoluminal System. All rights reserved; used with
permission from Intuitive Surgical
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and measures its own shape hundreds of times per second, representing and displaying throughout the procedure the shape and position of the catheter relative to the
anatomy (Fig. 5). The catheter also provides feedback to
the robotic control algorithm that maintains the intended
position for the catheter instrument, enabling a fixed and
stable position and correcting for any deflections from
the intended position by providing extra force through
the appropriate pull-wire system. The technology and
instruments are immune to electromagnetic interference
and are unaffected by metallic objects or electromagnetic
fields.
Each investigator completed standardized training,
which allowed bronchoscopists to gain experience and
basic familiarity with the system through in-depth dry
lab in-service training, a porcine lab, and a cadaveric lab.
In-service training was completed prior to any clinical
cases primarily for support staff and included assistance
with room setup and process workflow.
Pre-procedure CT scans (0.75–1.25 mm slice thickness) were segmented using the system-specific PlanPoint™ planning software with pathway planning
completed and reviewed through a virtual simulation
(Fig. 6a and Fig. 6b). With the patient under general
anesthesia, standard airway examinations were initially
performed using a flexible bronchoscope and included
clearing of secretions and review of the normal anatomy
to be navigated. The SSRAB system was then docked to
the endotracheal tube via a magnetic adapter. After registration, navigation of the catheter to the target nodule
was completed under direct visualization and in accordance with the virtual plan created using the pre-procedure CT. When the target was reached, the vision probe
was removed and a combination of rEBUS and fluoroscopy were used to assess real-time information regarding
the nodule and to refine the biopsy location. After appropriate adjustments were made to the catheter position,
sampling commenced using the system-specific flexible
needle (Flexision™, 19G, 21G, or 23G) using the cloud
biopsy technique. Cloud biopsy, which describes the
systematic and consistent placement and/or redirection
of biopsy tools in specific sampling areas, was enabled
by the fine manipulation of the scope tip in any plane to
optimize the angle towards the target for further biopsies. The cloud biopsy facilitates the collection of samples from four different quadrants of a target nodule. The
bronchoscopist was able to perform this technique due
to the ability to make micro adjustments of the catheter
tip to optimize the biopsy zone. Forceps, cytology brush,
and/or bronchioalveolar lavage were used at the bronchoscopist’s discretion. Rapid on-site cytology evaluation
(ROSE) was available at 5 of 6 participating centers and
was used according to institution practice and was not
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Fig. 2 Procedural screenshot from one case. Top monitor screens: virtual airway view showing catheter within airway tree; blue ball represents
target; green subway view at bottom shows the progress of the catheter to the target; drive force displayed on the right. Bottom monitor screens:
(upper left) virtual target with target view; (bottom left) integrated EBUS view; (center) fluoroscopy view of catheter with tool extension; (right side)
informational screen displaying distance to virtual target, anatomy borders, orientation guide, and catheter tip bend radius

standardized. Following the procedure, a fluoroscopic
check for pneumothorax was performed; in the same
anesthesia event, EBUS-TBNA staging (where indicated)
was performed. A chest x-ray was taken at least one-hour
post-procedure to assess for delayed pneumothorax.
Both the nodule size (assessed in axial, coronal and
sagittal planes) as well as the distance of the closest edge

of the target nodule to the closest pleura or fissure were
both based on pre-procedure CT scans. Bronchial generation count was assessed with the trachea representing
generation 0 and each subsequent carina or bifurcation/
trifurcation counting as an additional generation based
on the pre-procedure CT and typically using the segmented model. Each bronchoscopist assessed the nodule
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Fig. 3 Another screenshot from a case showing (top) the catheter reaching the virtual target and (bottom) fluoroscopic view of catheter bend to
the apical lesion

characteristics including presence of bronchus sign on
pre-procedure CT and rEBUS visualization during the
procedure according to individual practice. Registration
time was the total time necessary to complete registration prior to the start of navigation; biopsy time (using
SSRAB for the peripheral nodule) was the time from
first biopsy tool insertion to last peripheral biopsy tool
withdrawn. Procedure time specifically for the SSRAB
system was measured from time of catheter insertion to

withdrawal; durations of airway survey prior to the use
of Ion nor the duration of further diagnostic procedures,
including EBUS-TBNA, were not included in these times.
Use of a PlanPoint-generated path reflected whether the
bronchoscopist followed a system-generated pathway to
the virtual target nodule. Catheter positions represented
the unique parked locations of the catheter tip in relation
to the nodule. Tool passes reflected the total number of
biopsy tools passed through the catheter, with each tool
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Fig. 4 Catheter instrument (3.5 mm outer diameter) with vision
probe in articulated position. All rights reserved; used with
permission from Intuitive Surgical

counted separately and no reliance on sample acquisition.
Distance between the catheter tip and the closest edge of
the virtual target when the catheter was parked prior to
biopsy was displayed on the system cart monitor. Adverse
events related to the bronchoscopy procedure were collected, including any type of pneumothorax and bleeding
that did not stop spontaneously or that required intervention. Subjects were followed at 10 days and 30 days
post-procedure.
The purpose of this stage of the study was to provide
participating investigators and support staff their first
human experience with the SSRAB system; safety and
procedure outcomes were analyzed. Diagnostic yield
or sensitivity for malignancy were not assessed in this
stage. Data in the current analysis will not be used in
subsequent multicenter outcomes analyses. Subject and
procedure outcomes for this lead-in stage are presented
descriptively; categorical variables are summarized by
percentage; continuous variables are summarized by
median/IQR. The statistical software package SAS® version 9.4 (SAS Institute, Cary, NC, USA) was used.
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Results
Sixty subjects were enrolled across the six participating institutions, and a total of 67 nodules were targeted
for biopsy. The study protocol recommended the timing between the pre-procedure CT scan and the procedure day not to exceed 21 days. On average, the CTs
were taken approximately 5 days prior to the procedures
and approximately 30% of the enrolled subjects had their
CT scans the day of their procedures. Demographics are
described in Table 1. The median pretest probability of
malignancy using the Mayo/Swensen model was 46.3%
(IQR: 23.8, 77.3) [9]; the majority (76.7%) of subjects
were classified as American Society of Anesthesiologists
(ASA) III.
Nodule characteristics are provided in Table 2. Median
axial, coronal, and sagittal dimensions were each 17.5,
16.0, and 16.2 mm, respectively, and the median largest cardinal diameter was 20.0 mm. Approximately half
(52.3%) of nodules were located in the upper lobes and
82.1% of nodules were solid. Nodules were predominately
extraluminal as assessed visually and the median distance
from the outer edge of the nodule to the nearest pleura or
fissure was 4.0 mm (IQR: 0.0, 15.0), with approximately
31% in contact with the pleura or fissure as measured on
the pre-procedure CT scan. A bronchus sign was present
for 32.7% of nodules. Median bronchial generation count
was 7.0 (IQR: 6.0, 8.0).
Procedural characteristics, including the median duration of each stage of the procedure, are provided (Table 3).
Navigation planning pre-procedure was 10.0 min (IQR:
5.0, 15.0), and the median duration of the procedures
from catheter in–to catheter out was 66.5 min (IQR: 50.0,
85.5) including sampling of multiple nodules within the
same subject (7 cases, each with 2 nodules biopsied) as
well time associated with ROSE results and/or obtaining
multiple samples. ROSE was completed in 78.3% of cases.

Fig. 5 Image illustrating shape-sensing technology along catheter’s entire length. All rights reserved; used with permission from Intuitive Surgical
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Fig. 6 a, b Segmented CT scans of the same subject from PlanPoint planning software from two orientations, both of which show the target
nodule, identified pathway, and anatomy border

Once registration was completed, navigation to the first
nodule took 5.0 min (IQR: 3.0, 10.0). In nearly all (93.1%)
of the cases, the PlanPoint path was used to reach the target nodule. During the biopsy sequence using a needle
first, forceps, and/or cytology brush, there was an average of four catheter tip positions. There was a median of
13 biopsy tool passes per procedure, and rEBUS was used
for 66 out of 67 nodules. rEBUS was not attempted in two

cases due to technical due to technical or clinical reasons at the discretion of the proceduralist. The remaining five nodules were in the lower lobe, and three did not
have CT bronchus sign. The median time to achieve first
rEBUS visualization was 8 min from navigation start. The
use of rEBUS achieved visualization of 89.4% of nodules
where rEBUS was attempted; of nodules visualized with
rEBUS, an initial concentric view was obtained in 39%
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Table 1 Baseline characteristics of subjects (n = 60 subjects)

Table 3 Procedural characteristics (n = 60 subjects)

Age, median, y (IQR)

70.7 (63.1, 76.6)

Duration, median min (IQR)

BMI, median kg/m2 (IQR)

25.0 (22.9, 31.6)

Navigation planning

10.0 (5.0, 15.0)

Procedure (scope in to scope out)

66.5 (50.0, 85.5)

Variable

Outcome

Gender, n (%)

Variable

Result

Female

35 (58.3)

Registration

8.5 (5.0, 14.0)

Male

25 (41.7)

Navigation to 1st nodule

5.0 (3.0, 10.0)

Pretest probability of malignancy, median % (IQR) a

46.3 (23.8, 77.3)

Biopsy completion

31.5 (25, 46.5)

Lymph node staging performed, n (%)

47 (78.3)

ASA class, n (%)
II

14 (23.3)

PlanPoint path used, n (%)

54 (93.1)

III

46 (76.7)

Time to 1st rEBUS visualization, min (IQR)

8.00 (4.0, 13.5)

Catheter positions, n (IQR)

4.0 (2.0, 7.0)

Tool passes, median n (IQR)

13.0 (8.0, 15.0)

IQR interquartile range, BMI body mass index, ASA American Society of
Anesthesiologists
a

Swensen’s Formula: low risk < 5%; indeterminate risk 5–65%; high risk > 65%;
from reference [9]

Table 2 Nodule characteristics (n = 67 nodules)
Variable

Axial

17.5 (12.0, 24.0)

Coronal

16.0 (11.8, 21.0)

Sagittal

16.2 (12.0, 22.0)

Largest cardinal diameter

20.0 (14.0, 27.0)

Lobe location, n (%)
LLL

8 (11.9)

LUL

18 (26.9)

RLL

21 (31.3)

RML

3 (4.5)

RUL

17 (25.4)

Distance from pleura or fissure, median mm (IQR)

4.0 (0.0, 15.0)

Bronchial generation count, median n (IQR)

7.0 (6.0, 8.0)

Location, n (%)a
Endoluminal

10 (15.4)

Extraluminal

55 (84.6)

Nodule type, n (%)
Solid

55 (82.1)

  Cavitary

4

Semi-solid

12 (17.9)

CT Bronchus sign present, n (%)

25 (37.3)

rEBUS attempted, n (%)

66 (98.5)

rEBUS visualization, n (%)b

59 (89.4)

  Concentric, initially

23 (40)

  Eccentric converted to concentric

8 (13.6)

  Eccentric

28 (47.5)

IQR interquartile range, LLL left lower lobe, LUL left upper lobe, RLL right lower
lobe, RML right middle lobe, RUL right upper lobe, rEBUS radial endobronchial
ultrasound
2 subjects had early termination

b

rEBUS visualization is based on nodules attempted

 Needlec

58 (100)

Forceps

40 (69)

Brush

28 (48.3)

IQR interquartile range

Outcome

Size, median mm (IQR)

a

Tools used, n (%)a,b

a

Tools used out of 58 completed procedures; 2 subjects with early termination
not included

b

More than one tool may have been used per case

c

System-specific Flexision needle

of visualized nodules, while an additional 13.6% of nodules that were initially found to have an eccentric view
became concentric after further adjustment and creation
of a path to the nodule.
Biopsy completion, whereby a tool was passed through
the catheter and a tissue sample obtained, was 96.7% for
all subjects and 97.0% for all nodules (Table 4). Among
completed biopsies, the median distance from the catheter tip to the edge of the virtual target was 7.0 mm (IQR:
2.0, 12.0). There were two subject cases where biopsies
were not attempted and an alternative method was used.
In one case, the CT slice thickness was incompatible for
registration; the case was completed using bronchoscopy
with rEBUS. In the other case, the physician was unable
to reach the nodule due to the lack of a patent airway
and the procedure was completed using an esophageal
approach using a cEBUS scope (EUS-B).
No serious adverse events were reported, including no
pneumothorax or airway bleeding of any grade [10, 11].
Two complications were reported, both of which were
classified as Common Terminology Criteria for Adverse
Event (CTCAE) grade 2 [12]. One subject experienced
cardiac arrhythmia during the procedure, which was
treated with medication with anesthesia and resolved
immediately. The subject did not have any symptoms
post-procedure and was discharged. Another subject
developed pneumonia 48 h post-procedure and was
treated with oral antibiotics at home with resolution of
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Table 4 Biopsy outcomes
Variable

Outcome

Biopsy completion, n (%)a
Subject level (n = 60)

58 (96.7)
95% CI: 92.1%, 100%b

Nodule level (n = 67)

65 (97.0)
95% CI: 92.9%, 100%b

Closest distance to nodule, median mm (IQR)c

7.0 (2.0, 12.0)

Serious adverse events, n (%)

0 (0)

Pneumothorax (with or without chest tube)

0 (0)

Airway bleeding (with or without intervention)

0 (0)

Other

0 (0)

Complications, n (%)

2 (3.3)

Cardiac arrhythmia, CTCAE grade 2 (intra-proce‑
dure)

1 (1.7)

Pneumonia, CTCAE grade 2 (post-procedure)

1 (1.7)

IQR interquartile range, CI confidence interval
CTCAE Common Terminology Criteria for Adverse Events; from reference 11
a
b
c

Biopsy completion = tool passed through catheter and a sample was obtained
95% Confidence Interval calculated using the Wald method

Closest distance from tip of catheter to edge of the virtual nodule

symptoms after approximately 10 days. Neither complication was attributed to the SSRAB system.

Discussion
Although the standard of care for the majority of incidentally found pulmonary nodules is active surveillance, any
nodule greater than 8 mm with a moderate pretest probability potentially warrants biopsy [13]. The introduction of new technologies, such as ENB and rEBUS have
advanced bronchoscopy, but despite these technologies
and tools, the reported diagnostic yield for peripheral
nodules < 2 cm is 40–67% [1, 7, 14, 15].
The early data from pre-clinical studies and the singlecenter first human use experience with SSRAB suggest
that this very stable and sensitive platform allows bronchoscopists to guide tools and localize peripheral tumors
to a higher degree than was previously possible [2]. The
lead-in results for the larger PRECIsE Study of the Ion
Endoluminal System are the earliest cases performed at
six centers by eleven physicians, including both interventional pulmonologists and thoracic surgeons. None of
the physicians had used the SSRAB system prior to these
cases, and this initial series was limited to the first 10
cases for each center or the first 5 cases each for centers
with more than one bronchoscopist.
Small peripheral nodules, which historically have
low diagnostic yields, were targeted. The SSRAB technology facilitated navigation to this type of nodule.
Despite the introductory nature of the technology for
the bronchoscopists, they approached nodules with a

median axial size < 18 mm. The ability to drive the catheter to the target and then fix the catheter in location
allowed passage of rEBUS, a system-specific flexible
biopsy needle, forceps, or brushes without deviation
from the target. Significant in each case was the ability of the Flexision needle to traverse very tight angles
into peripheral airways allowing for repeat sampling
at the same location, as illustrated in Fig. 7. This initial
experience suggests the investigators were able to target small peripheral lesions during the first few cases,
expeditiously and safely; however, diagnostic sensitivity and diagnostic yield metrics associated with nodules
of this size warrants further investigation. While the
clinical utility of the system will be reported in future
publications, in most cases, EBUS lymph node staging
was performed after biopsy during the same procedure
in order to potentially reduce CT-body divergence (single anesthetic event) optimizing workflow for comprehensive diagnosis of suspicious nodules with complete
staging in a single procedure [16].
In an operating room or bronchoscopy suite, each minute is a unit of time that influences personnel use and
direct costs. Our cases had a median procedure time of
66.5 min and total biopsy workflow time of 31.5 min.
Folch et al. recently reported data from a large multicenter evaluation of ENB, 92.2% of whom performed > 5
ENB procedures per month with experienced ENB teams
[7]. Their median total procedure time was 52 min and
median total ENB-specific procedure time was 25 min.
Given the established teams and navigational platforms
in their reported study, we are encouraged by our initial
experience and anticipate comparable procedural times
using the SSRAB system in the subsequent phase of the
PRECIsE study.
Because the unique shape-sensing feedback (rather
than electromagnetic navigation) is fundamental to the
Ion system, biopsy tools can be introduced through the
catheter and simultaneous use of fluoroscopy can be
incorporated throughout the procedure without affecting navigational accuracy. The real-time feedback allows
for frequent referencing to the virtual target throughout
the procedure and does not require movement of equipment into and/or out of the procedure field, providing for
continuity in procedural workflow and facilitating stability of the catheter when positioned for biopsy. The physician can potentially correct for perceived CT-to-body
divergence during navigation by identifying airways on
the camera image and subsequently comparing them to
the virtual image. If the physician believes the catheter is
in the wrong airway, alternative airways can be quickly
identified and accessed. Similarly, the virtual nodule position can be adjusted for rEBUS and fluoroscopic input,
allowing an organized, accurate biopsy procedure.
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Fig. 7 Display of catheter on the system monitors during biopsy. The catheter position is shown in green and is interlaid on the virtual airway map.
On the bottom screen, fluoroscopy reveals the tight bend of the catheter through the airways to reach the target nodule. Distance to the nearest
and farthest edge of the target nodule is displayed at the lower right corner

With one-third of the nodules at least 8 generations
out, the investigators perceived that SSRAB accessed
nodules in peripheral locations. With the nodule identified, the combination of catheter size and flexibility,
real-time shape feedback, and live visualization during
navigation facilitated not only reaching within 7.0 mm of
the virtual target but also passage of biopsy tools, including the Flexision biopsy needle, through any bend of the

catheter to obtain tissue samples from the intended location. These outcomes suggest SSRAB will contribute significantly to the management of suspicious peripheral
nodules.
Sampling, using the flexible needle, forceps, and/or
brush biopsy tools, was performed with virtual targeting, fluoroscopy, and rEBUS. The shape-sensing technology detected and corrected for any catheter tip deflection

Simoff et al. BMC Pulm Med

(2021) 21:322

that occurred from the insertion or removal of the rEBUS
catheter or biopsy tools. By leveraging the capability to
perform cloud biopsies, the broncoscopist can use the
virtual, fluoroscopic, and ultrasound images to further
localize the lesion for additional sampling, updating the
position of the virtual target based on the gained realtime information. That the nodule visualization rate
using rEBUS was 89.4% at the terminus of navigation
demonstrates the initial localization success that SSRAB
may provide, despite the majority of nodules not having a bronchus sign on pre-procedure CT. Early rEBUS
literature reported visible lesions in approximately 67%
of cases while more recent studies have reported an
increase to 96% [17, 18]. rEBUS visualization characteristics and determination of true nodule identification
versus artifact or atelectasis interpreted as nodule visualization is being studied [19]. Future studies may benefit
from a standardized definition and review of imaging to
confirm rEBUS visualization and characteristics.
Despite the high biopsy rate (96.7%) in the current
study, there were no events of pneumothorax or hemorrhage. This compares with the full cohort in the NAVIGATE study where the overall pneumothorax rate was
4.3% and, for those pneumothorax graded CTCAE ≥ 2,
the rate was 2.9%. The ENB-related bronchopulmonary
hemorrhage rate graded CTCAE ≥ 2 was 1.5% [7]. The
encouraging safety profile should be noted in the context of this series describing the first human use of this
technology for each bronchoscopist and suggests this
technology’s comparable safety profile to guided bronchoscopic approaches and significantly improved over
percutaneous biopsy approaches. While encouraging,
safety speculation is based on a limited number of subjects and further safety data from a larger cohort is
forthcoming. As a remote-manipulator system, one of
the limitations of robotic systems is the lack of haptic
feedback that the physician may be accustomed to when
performing manual bronchoscopy. During our initial
experience, the use of visual cues provided feedback and
confidence during navigation and sampling, supported
by the low complication rate and the absence of observed
airway trauma. Future publications will evaluate the sensitivity of malignancy and yield associated with this system relative to other approaches to further contextualize
the value of Ion’s safety profile.
Given the lead-in nature of this study, it has inherent
limitations. All of the bronchoscopists and their teams
were new to SSRAB technology in live cases and, thus,
the described data were gained early in their learning
curve. However, because they are highly experienced
with bronchoscopic procedures, including with other
navigation platforms, their experiences with SSRAB
may not reflect the real world of bronchoscopists who
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may be early in their interventional pulmonary practice. As with any new technology, the use of SSRAB, its
integration into the workflow, and the experience of the
bronchoscopist and team all can affect durations and
outcomes. Despite the fact that each center and physician
had significant experience with ENB and other advanced
diagnostic approaches, a standardized training program
with mentorship provided by technical staff was completed prior to the first human experience. Performance
metrics such as yield and sensitivity were not assessed
due to limited follow-up, however performance metrics met the purpose of the lead-in phase. Further study
is needed to evaluate performance. Other limitations
include the enrollment of subjects according to controlled eligibility criteria, although the study’s eligibility
criteria modeled the population typically indicated for
this type of biopsy procedure. Furthermore, the specific
biopsy sequence and tool usage, as well as assessment of
characteristics of CT bronchus sign or rEBUS visualization was not standardized: the view—eccentric or concentric—was determined by physician assessment. This
was by design a goal of this lead-in stage to understand
the real-world workflow and experience associated with
this new technology. Last, the intent of the current single-arm analysis was generation of evidence regarding
early experience. Future comparative studies should be
considered in those centers where experience and proficiency with current technologies have been obtained.
Strengths of the study are its multicenter design and the
prospective collection and reporting of data from each
bronchoscopist’s first cases.

Conclusions
In this early experience with the Ion Endoluminal System and its shape-sensing navigation technology, bronchoscopists were successful in their ability to safely
drive the catheter tip within close proximity of the virtual target for peripheral nodules, and they were able
to obtain one or more biopsy samples of small, peripherally based nodules and—when necessary—perform
lymph node staging within the same procedure. Both site
and research-specific experiences have led to modified
approaches and workflows with SSRAB, setting the stage
for the full prospective evaluation, which will be reported
at study completion. This initial, multicenter experience
is encouraging and suggests the significant role SSRAB
may play in the management of pulmonary nodules.
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